AtriCure, Inc. (ATRC) FY2026 Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
AtriCure, Inc. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income (loss) → Net cash from operating activities: $8,955,000.00Share-based compensation expense → Operating adjustments reconciliation: $12,313,000.00Accrued liabilities → Operating adjustments reconciliation: $3,448,000.00Accounts payable → Operating adjustments reconciliation: $3,445,000.00Depreciation → Operating adjustments reconciliation: $2,923,000.00Amortization of intangible assets → Operating adjustments reconciliation: $2,384,000.00Other current assets → Operating adjustments reconciliation: $1,202,000.00Other non-cash adjustments → Operating adjustments reconciliation: $469,000.00Amortization of deferred financing costs → Operating adjustments reconciliation: $105,000.00Operating adjustments reconciliation → Net cash from operating activities: $13,237,000.00Operating adjustments reconciliation → Accounts receivable: $8,761,000.00Operating adjustments reconciliation → Inventories: $2,871,000.00Operating adjustments reconciliation → Other noncurrent assets and liabilities: $1,420,000.00Proceeds from stock option exercises and employee stock purchase plan → financing reconciliation: $3,912,000.00financing reconciliation → Net cash from financing activities: $3,262,000.00financing reconciliation → Payments on debt, leases and financing obligation: $334,000.00financing reconciliation → Shares repurchased for payment of taxes on stock awards: $314,000.00financing reconciliation → Payment of financing costs and debt fees: $2,000.00Net cash used in investing activities → investing reconciliation: $3,766,000.00investing reconciliation → Purchases of property and equipment: $3,766,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $146,165,000.00Net cash from operating activities → Cash sources and uses: $22,192,000.00Net cash from financing activities → Cash sources and uses: $3,262,000.00Cash sources and uses → Exchange-rate effect: $67,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $167,786,000.00Cash sources and uses → Net cash used in investing activities: $3,766,000.00Net income (loss): $8,955,000.00Net income (loss)+$8.96 MShare-based compensation expense: $12,313,000.00Stock-based compensation+$12.31 MDepreciation: $2,923,000.00Depreciation expense+$2.92 MAmortization of intangible assets: $2,384,000.00Intangible amortization+$2.38 MAmortization of deferred financing costs: $105,000.00Debt issuance cost amortization+$105.00 KOther non-cash adjustments: $469,000.00Other operating, net+$469.00 KAcquired in-process research and development expense: $0.00Accounts receivable: -$8,761,000.00Accounts receivable−$8.76 MInventories: -$2,871,000.00Inventories−$2.87 MOther current assets: $1,202,000.00Other current assets+$1.20 MAccounts payable: $3,445,000.00Accounts payable+$3.45 MAccrued liabilities: $3,448,000.00Accrued liabilities+$3.45 MOther noncurrent assets and liabilities: -$1,420,000.00Other noncurrent items−$1.42 MNet cash from operating activities: $22,192,000.00Operating cash+$22.19 MOperating adjustments reconciliation: $26,289,000.00Payments on debt, leases and financing obligation: -$334,000.00Debt & lease obligations repaid−$334.00 KProceeds from stock option exercises and employee stock purchase plan: $3,912,000.00Option & stock plan proceeds+$3.91 MShares repurchased for payment of taxes on stock awards: -$314,000.00Stock-award tax withholding−$314.00 KPayment of financing costs and debt fees: -$2,000.00Debt issuance costs−$2.00 KNet cash from financing activities: $3,262,000.00Financing cash+$3.26 Mfinancing reconciliation: $3,912,000.00Purchases of property and equipment: -$3,766,000.00PP&E purchases−$3.77 MAcquisitions, including in-process research and development: $0.00Proceeds from capital grant: $0.00Net cash used in investing activities: -$3,766,000.00. Cash required to fund net payments.Investing cash−$3.77 Minvesting reconciliation: $3,766,000.00Cash sources and uses: $171,619,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $146,165,000.00Beginning cash$146.17 MEnding cash: Cash, cash equivalents, and restricted cash: $167,786,000.00Ending cash$167.79 MExchange-rate effect: -$67,000.00FX effect−$67.00 KCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flow$18.43 MOperating cash − cash spent on PP&ECash flow / Net income2.48×Operating cash flow ÷ net incomeNet cash change+$21.62 MEnding cash − beginning cash
Chart details

AtriCure, Inc. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
146,165,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
22,192,000 US dollars. Net cash provided.
Net income (loss)
8,955,000 US dollars
Share-based compensation expense
12,313,000 US dollars
Depreciation
2,923,000 US dollars
Amortization of intangible assets
2,384,000 US dollars
Amortization of deferred financing costs
105,000 US dollars
Other non-cash adjustments
469,000 US dollars
Acquired in-process research and development expense
0 US dollars
Accounts receivable
negative 8,761,000 US dollars
Inventories
negative 2,871,000 US dollars
Other current assets
1,202,000 US dollars
Accounts payable
3,445,000 US dollars
Accrued liabilities
3,448,000 US dollars
Other noncurrent assets and liabilities
negative 1,420,000 US dollars
Investing activities
negative 3,766,000 US dollars. Net cash used.
Purchases of property and equipment
negative 3,766,000 US dollars
Acquisitions, including in-process research and development
0 US dollars
Proceeds from capital grant
0 US dollars
Financing activities
3,262,000 US dollars. Net cash provided.
Payments on debt, leases and financing obligation
negative 334,000 US dollars
Proceeds from stock option exercises and employee stock purchase plan
3,912,000 US dollars
Shares repurchased for payment of taxes on stock awards
negative 314,000 US dollars
Payment of financing costs and debt fees
negative 2,000 US dollars
Operating adjustment reconciliation
26,289,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
3,912,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
3,766,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 67,000 US dollars
Ending cash on Jun 30, 2026
167,786,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
171,619,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
21,621,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
2.48×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
22,192,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
3,766,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
18,426,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $13.24M after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 22,192,000 US dollars minus 3,766,000 US dollars equals 18,426,000 US dollars.
AtriCure, Inc. (ATRC) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!